Announcements Trials

Browse Landscape

Phase

Phase 4 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 77 Radiotherapy 73 Prednisone 66 Leuprolide 51 Goserelin 49 Gemcitabine 49 Cisplatin 48 bicalutamide 46 enzalutamide 43 Androgen Antagonists 36 pembrolizumab 32 Abiraterone Acetate 31 Mitomycin 29 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28 Magnetic Resonance Spectroscopy 28 Carboplatin 27 Flutamide 25 Nivolumab 24 Triptorelin Pamoate 23 Sunitinib 23 apalutamide 22 Radiation 22 Doxorubicin 20 darolutamide 19 abiraterone 18 Gonadotropin-Releasing Hormone 18 cabozantinib 17 atezolizumab 16 Specimen Handling 16 Radiosurgery 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Amoxicillin-Potassium Clavulanate Combination × Genitourinary × Clear all

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡